61st Annual Congress of the European Association for the Study of Diabetes

Czech version

Authors: Martin Jozef Péč; Marián Mokáň
Authors‘ workplace: I. interná klinika JLF UK a UNM, Martin
Published in: Forum Diab 2025; 14(2): 144-147
Category:

Sources

61^st EASD Annual Meeting of the European Association for the Study of Diabetes : Vienna, Austria, 15–19 September 2025. Diabetologia 2025; 68(Suppl 1): 1–754. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–025–06497–1>.

Mathieu C, Wych J, Hendriks AEJ et al. Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial. Lancet 2025; 406(10510): 1375–1388. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(25)01674–5>.

Wharton S, Aronne LJ, Stefanski A et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med 2025; Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2511774>.

McGuire DK, Marx N, Mulvagh SL et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med 2025; 392(20): 2001–2012. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa2501006>.

Fadini GP. Can Dual Incretin Receptor Agonists Exert Better Cardiovascular Protection than Selective GLP-1 Receptor Agonists? Highlights from SURPASS-CVOT. Diabetes Ther 2025; 16(10): 1893–1898. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–025–01784-x>.

Wharton S, Freitas P, Hjelmesæth J et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 2025; S2213–8587(25)00226–8. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(25)00226–8>.

Lingvay I, Bergenheim SJ, Buse JB et al. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 2025; S2213–8587(25)00225–6. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(25)00225–6>.